| 6186- | Cuc, | Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-453 |
| 6188- | Cuc, | Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation |
| - | in-vitro, | Var, | NA |
| 6189- | Cuc, | Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 6190- | Cuc, | Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells |
| - | in-vitro, | Colon, | SW480 |
| 6191- | Cuc, | Growth inhibitory effect of Cucurbitacin E on breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6192- | Cuc, | Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway |
| - | vitro+vivo, | CRC, | NA |
| 6193- | Cuc, | Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways |
| - | in-vitro, | Liver, | HUH7 |
| 6194- | Cuc, | Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats |
| - | in-vivo, | Nor, | NA |
| 6195- | Cuc, | Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends |
| - | Review, | Var, | NA |
| 6185- | Cuc, | Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA |
| 6184- | Cuc, | Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells |
| - | vitro+vivo, | PC, | NA |
| 6197- | Cuc, | Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH‑SY5Y human neuroblastoma cells |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 6198- | Cuc, | Comparison of the pharmacokinetic profiles of three triterpenoids after oral administration of a cucurbitacin tablet and nanosuspension by UHPLC-MS/MS |
| - | in-vivo, | Nor, | NA |
| 6199- | Cuc, | Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 6200- | Cuc, | GEM, | Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer |
| - | in-vivo, | PC, | NA |
| 6201- | Cuc, | Cucurbitacin B and Its Derivatives: A Review of Progress in Biological Activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6202- | Cuc, | Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms |
| - | Review, | Var, | NA |
| 6203- | Cuc, | immuno, | Isocucurbitacin B targets STAT3 to induce ferroptosis and promote anti-PD1 immunotherapy responses in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | 4T1 |
| 6204- | Cuc, | Preliminary investigation of the anti-colon cancer activity of cucurbitacin C from cucumber: A network pharmacological study and experimental validation |
| - | in-vitro, | Colon, | HCT116 |
| 6205- | CUR, | Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis |
| - | Review, | Var, | NA |
| 5783- | CUR, | EGCG, | The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice |
| - | in-vivo, | Nor, | NA |
| 5229- | CUR, | Activation of Transcription Factor NF-κB Is Suppressed by Curcumin (Diferuloylmethane) |
| - | in-vitro, | Melanoma, | NA |
| 6050- | CUR, | SeNPs, | Efficacy of curcumin-selenium nanoemulsion in alleviating oxidative damage induced by aluminum chloride in a rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 5397- | CUR, | SFN, | RES, | EGCG, | Ash | Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| - | in-vivo, | AD, | NA |
| 4175- | CUR, | Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress |
| - | in-vivo, | AD, | NA |
| 4171- | CUR, | Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons |
| - | in-vivo, | Nor, | NA |
| 3753- | CUR, | Gala, | A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics Study |
| - | Study, | AD, | NA |
| 3857- | CUR, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3856- | CUR, | Curcumin induces IL-6 receptor shedding via the ADAM10 proteinase |
| - | in-vitro, | AD, | NA |
| 3793- | CUR, | Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation |
| - | in-vivo, | AD, | NA |
| 3860- | CUR, | Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3861- | CUR, | Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment? |
| - | Review, | Var, | NA |
| 3862- | CUR, | RES, | The metalloproteinase ADAM10: A useful therapeutic target? |
| - | Review, | AD, | NA |
| 3794- | CUR, | Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities |
| - | Review, | AD, | NA |
| 3831- | CUR, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3795- | CUR, | Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence |
| - | Review, | AD, | NA |
| 3797- | CUR, | Curcumin reverses cognitive deficits through promoting neurogenesis and synapse plasticity via the upregulation of PSD95 and BDNF in mice |
| - | in-vitro, | AD, | NA |
| 3760- | CUR, | GI, | CAP, | RosA, | PI | Extending the lore of curcumin as dipteran Butyrylcholine esterase (BChE) inhibitor: A holistic molecular interplay assessment |
| - | Review, | Nor, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3586- | CUR, | PI, | Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers |
| - | in-vivo, | Nor, | NA |
| 3585- | CUR, | Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer |
| - | Study, | Nor, | NA |
| 3584- | CUR, | Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids |
| - | Review, | AD, | NA |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| - | in-vivo, | Nor, | NA |
| 3581- | CUR, | Curcumin Attenuated Neurotoxicity in Sporadic Animal Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3580- | CUR, | Curcumin Acts as Post-protective Effects on Rat Hippocampal Synaptosomes in a Neuronal Model of Aluminum-Induced Toxicity |
| - | in-vivo, | AD, | NA |
| 3579- | CUR, | AgNPs, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | Nor, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3577- | CUR, | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| - | Trial, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid